Conflicts of interest: L Wei has received research support and/or consulting fees from Bristol-Myers Squibb, Roche, and Novartis. L Zhang has received consulting fees from Bristol-Myers Squibb. X Dou has received speaking fees from Bristol-Myers Squibb, GSK, Roche, and Novartis. J Sun has received research support from Roche and Novartis. H Li and JC Lopez-Talavera are employees of Bristol-Myers Squibb. H Rao, J Shang, H Chen, J Li, Q Xie, Z Gao, L Wang, J Wei, J Jiang, Y Sun, R Yang, H Zhang, Z Gong, L Zhao, J Niu, H You, Z Chen, Q Ning, G Gong, S Wu, W Ji, Q Mao, H Tang, S Li, S Wei, J Sun, J Jiang, L Lu, J Jia, and H Zhuang have no conflicts.
Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection
Article first published online: 19 FEB 2014
© 2013 The Authors. Journal of Gastroenterology and Hepatology published by Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing and Wiley Publishing Asia Pty Ltd.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Journal of Gastroenterology and Hepatology
Volume 29, Issue 3, pages 545–553, March 2014
How to Cite
Rao, H., Wei, L., Lopez-Talavera, J. C., Shang, J., Chen, H., Li, J., Xie, Q., Gao, Z., Wang, L., Wei, J., Jiang, J., Sun, Y., Yang, R., Li, H., Zhang, H., Gong, Z., Zhang, L., Zhao, L., Dou, X., Niu, J., You, H., Chen, Z., Ning, Q., Gong, G., Wu, S., Ji, W., Mao, Q., Tang, H., Li, S., Wei, S., Sun, J., Jiang, J., Lu, L., Jia, J. and Zhuang, H. (2014), Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection. Journal of Gastroenterology and Hepatology, 29: 545–553. doi: 10.1111/jgh.12398
- Issue published online: 19 FEB 2014
- Article first published online: 19 FEB 2014
- Accepted manuscript online: 3 OCT 2013 11:18AM EST
- Manuscript Accepted: 17 AUG 2013
- China National Science and Technology Major Project for Infectious Diseases Control during the 11th Five-Year Plan Period. Grant Numbers: 2008ZX10002-013, 2008ZX10002-012
- 12th Five-Year Plan Period. Grant Number: 2012ZX10002003
- Bristol-Myers Squibb
Vol. 29, Issue 5, 1126, Article first published online: 21 APR 2014
- natural history
Background and Aim
Chronic hepatitis C virus (HCV) infection is relatively frequent in China. This study investigated the clinical, demographic, and viral and host genetic characteristics that may influence disease manifestations and clinical management.
In this cross-sectional observational study, treatment-naïve Han ethnic adults with recently confirmed chronic HCV infection were enrolled at 28 hospitals across China. HCV genotype and host interleukin 28B (IL28B) genotypes were determined and compared with patient demographic parameters and medical status.
Among the 997 HCV-positive patients analyzed, 56.8% were infected with HCV genotype 1b, followed in prevalence by genotypes 2, 3, and 6, with substantial regional variation. Overall, 84.1% of patients were IL28B genotype CC (rs12979860), with little regional variation. Cirrhosis was reported in 10.1% of patients and was significantly associated with hepatitis B virus coinfection, low HCV viral load, low serum alanine aminotransferase, high serum aspartate aminotransferase, diabetes, and high pickled food consumption. Medical procedures were common transmission risk factors; however, lifestyle-associated risk factors, including intravenous drug abuse and tattoos or piercings, were more common in patients with HCV genotype 3 or 6.
Most HCV-infected Han Chinese patients were IL28B genotype CC (rs12979860). HCV genotypes varied by geographic region, and disease characteristics differed according to HCV genotype. Relatively frequent detection of advanced liver disease may reflect limitations on access to antiviral therapy, and suggests that greater awareness of factors that influence HCV-associated disease may help avoid clinical complications and improve patient outcomes.